Cytoskeleton-interacting activity of geiparvarin, diethylstilbestrol and conjugates

被引:14
作者
Bocca, C [1 ]
Gabriel, L [1 ]
Miglietta, A [1 ]
机构
[1] Univ Turin, Dept Expt Med & Oncol, I-10125 Turin, Italy
关键词
cytoskeleton; geiparvarin; DES; derivatives; paclitaxel; cytotoxicity;
D O I
10.1016/S0009-2797(01)00261-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Geiparvarin, a natural compound isolated from the leaves of Geijera parviflora, inhibits the growth of various tumor cell lines with a mode of action which may be attributed to its anti-microtubular activity. Our previous findings indicated that gelparvarin is able to inhibit the in vitro polymerization of tubulin and to derange the microtubular network in fibroblasts more effectively in the presence of paclitaxel. To further explore its biological activity here we have studied the effects exerted on the other components of the cytoskeleton by geiparvarin and two derivatives obtained by conjugating the 3(2H)-furanone ring of geiparvarin with diethylstilbestrol (DES). Firstly, observations by electron microscopy confirmed anti-microtubular properties, a near-total absence of microtubules is detected when tubulin is incubated with drugs in the presence of paclitaxel, whereas microtubule formation is not inhibited by drugs when assembly is induced by guanosine 5'-triphosphate (GTP). Immunofluorescence assays demonstrated that geiparvarin and DES act in a vinblastine-like fashion, causing a marked depletion of intermediate filaments while the network of microfilaments is not affected. Both the conjugates alter the 'stress fibers' organization of actin and disrupt the vimentin pattern; generally they derange cytoskeleton more markedly than the parent compounds. The cell growth inhibiting effects of geiparvarin and derivatives are dose-dependent, they vary according to the cell line used, when compounds were administered either alone or simultaneously with paclitaxel. Unlike other anti-microtubule agents, they do not exhibit cell-cycle compartment specificity and do not influence thymidine uptake in the cell. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:285 / 305
页数:21
相关论文
共 45 条
[1]  
Bai RL, 1996, CANCER RES, V56, P4398
[2]   QUALITATIVE STUDY OF THE INTERACTION MECHANISM OF ESTROGENIC DRUGS WITH TUBULIN [J].
CHAUDOREILLE, MM ;
PEYROT, V ;
BRAGUER, D ;
CODACCIONI, F ;
CREVAT, A .
BIOCHEMICAL PHARMACOLOGY, 1991, 41 (05) :685-693
[3]   Desoxyepothilone B:: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B [J].
Chou, TC ;
Zhang, XG ;
Balog, A ;
Su, DS ;
Meng, DF ;
Savin, K ;
Bertino, JR ;
Danishefsky, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) :9642-9647
[4]  
Cocconi G, 2000, CANCER-AM CANCER SOC, V88, P2731, DOI 10.1002/1097-0142(20000615)88:12<2731::AID-CNCR11>3.0.CO
[5]  
2-9
[6]  
Dark GG, 1997, CANCER RES, V57, P1829
[7]   NOVEL ROUTES TO FURAN-3(2H)-ONES - NEW SYNTHESES OF BULLATENONE AND GEIPARVARIN [J].
JACKSON, RFW ;
RAPHAEL, RA .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1984, (03) :535-539
[8]   SYNTHESIS AND CONFIGURATIONAL ASSIGNMENT OF GEIPARVARIN - A NOVEL ANTI-TUMOR AGENT [J].
JERRIS, PJ ;
SMITH, AB .
JOURNAL OF ORGANIC CHEMISTRY, 1981, 46 (03) :577-585
[9]   Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer [J].
Kelly, WK ;
Curley, T ;
Slovin, S ;
Heller, G ;
McCaffrey, J ;
Bajorin, D ;
Ciolino, A ;
Regan, K ;
Schwartz, M ;
Kantoff, P ;
George, D ;
Oh, W ;
Smith, M ;
Kaufman, D ;
Small, EJ ;
Schwartz, L ;
Larson, S ;
Tong, W ;
Scher, H .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :44-53
[10]   TUMOR INHIBITORS .111. STRUCTURE AND STEREOCHEMISTRY OF JATROPHONE, A NOVEL MACROCYCLIC DITERPENOID TUMOR INHIBITOR [J].
KUPCHAN, SM ;
SIGEL, CW ;
MATZ, MJ ;
GILMORE, CJ ;
BRYAN, RF .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1976, 98 (08) :2295-2300